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Objective：Recent epidermiologic studies suggested that alterations in folate metabolism as a result of 
polymorphism in the enzyme 5,10-methylenetetrahydrofolate reductase(MTHFR) have been frequently 
associated with neural tube defects, vascular disease, and some cancers. A common 677C→T polymor-
phism in the MTHFR gene results in thermolability and reduced MTHFR activity that decreases the pool 
of 5-methyltetrahydrofolate and increases the pool of 5,10-methylenetetrahydrofolate. A possible cause 
underlying altered DNA methylation could be an insufficient level of S-adenosylmethionine as a consequ-
ence of weaker alleles of MTHFR gene. Therefore, the weak MTHFR activity may underlie susceptibility 
to brain neoplasms. We now report the associations of MTHFR polymorphisms in three groups of adult 
brain tumors：gliomas, meningiomas and schwannomas.  
Methods：We analyzed DNA of 71 brain tumors and 254 age- and sex-matched controls with a case-
control study. MTHFR variant alleles were determined by a PCR-restriction fragment length polymorphism 
assay. 
Results：The incidence of the MTHFR 677TT genotype was higher among 20 schwannoma cases 
compared with that of 254 controls, conferring a 5-fold increase of the risk of schwannomas(odds ratio, 
OR=4.75；95% confidence index, CI=1.05-21.50). The homozygous mutant group had half the risk of 
meningioma(OR=0.42；95% CI = 0.11-1.58) compared with the homozygous normal or heterozygous 
genotypes. There was no significant difference in MTHFR 677TT genotype frequency between glioma 
group(19 cases) and control group(254 cases)(OR = 1.53；95% CI = 0.30-7.73). 
Conclusion：The data indicate that the homozygous 677TT MTHFR genotype confers the significantly 
higher risk of schwannoma and the lower risk of meningioma. However, our study had limited a statistical 
power because of the small sample size, which is reflected in the wide CIs. Hence, these findings need to 
be confirmed in larger populations. 
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Introduction 
 
The global and gene-specific anomalies of DNA methy-
lation contribute to the loss of proto-oncogene and tumor 
suppressor expression. There are some evidences that DNA 
methylation can be influenced by manipulating the availability 
of methyl group donors, such as folate23). Folate levels are 
influenced by 2 enzymes：5,10-methylenetetrahydrofolate 
reductase(MTHFR) catalyzing the conversion of 5,10-me-
thylenetetrahydrofolate(methylene THF) to 5-methyltetra-
hydrofolate(methyl THF), and methionine synthase(MTR) 
catalyzing the transfer of a methyl group from methyl THF 
to homocysteine. MTHFR is a critical enzyme in folate me-
tabolism34). Its product, 5-methyl THF, is the dominant form 
of folate in plasma, whereas the enzyme substrate, 5,10-
methylene THF, is found mainly intracellularly. 5-Methyl 
THF provides the methyl group for de novo methionine 
synthesis and DNA methylation33). Imbalanced DNA methy-
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lation, characterized by global genomic hypomethylation15,18) 
and the methylation of usually unmethylated CpG sites20,28), 
is observed consistently in colonic neoplasia25). A decreased 
5-methyl THF pool may affect DNA methylation and 
thereby contribute to carcinogenesis. On the other hand, the 
substrate for MTHFR, 5,10-methylene THF, is required for 
conversion of deoxyuridylate to thymidylate, and, thus, the 
depletion of this form of folate may interfere with the thymi-
dylate biosynthesis and result in development of deoxynu-
cleotide pool imbalance4). This leads to the accumulation of 
deoxyuridylate in DNA pool4) and the removal of this abno-
rmal base might labilize DNA to strand breaks2,5,10,14,27,30-32). 
A common mutation(677C→T：alanine-to-valine) has 
been identified in the MTHFR gene16,19). This homozygous 
mutation causes reduced enzyme activity about 30% of the 
normal activity16), leading to the reduced levels of circulating 
folate(5-methyl THF) and to the accumulation of 5,10-me-
thylene THF. Exploration of the association of this mutation 
with brain tumors therefore permits a further assessment of 
the role of folate in tumorigenesis and the relative importance 
of MTHFR genotype with the risk of the several types of 
brain tumors. 
 
Materials and Methods 
  
Patient selection 
Seventy-one unrelated patients(age range, 11-75 years；
mean age, 48.4 years；male, 45.2%) with glial tumor(19 
samples), meningioma(32 samples), or schwannoma(20 sa-
mples) were studied and compared with 254 Korean control 
subjects(age range, 21-89；mean age, 49.3 years；male, 
46.3%) who had not been diagnosed with vascular diseases 
and cancers. The patients with those brain tumors were 
enrolled from May, 2000 to April, 2002. Patients with the 
other pathology of brain tumor were not included. Tissues 
were collected with the informed consents of patients un-
dergoing tumor resection and the pathological diagnosis of 
tissues was confirmed by histological analysis. The tissues 
were snap-frozen in liquid nitrogen and stored at -70℃. We 
calculated odds ratios(ORs) and 95% confidence indices 
(CIs) for the association of the MTHFR genotype with brain 
tumors using unconditional logistic regression. 
 
DNA extraction and mutation analysis 
There are three MTHFR genotypes：mutant homozygotes 
(val/val：677TT), heterozygotes(val/ala：677CT), and 
wild-type homozygotes(ala/ala：677CC). The genotyping 
protocol for the detection of the MTHFR 677C→T polymor-
phism was adopted from the report of Frosst, et al16). This C
→T base pair substitution creates a HinfI restriction site. In 
brief, 0.5-2.0μg of human genomic DNA was amplified 
with 50ng each of forward primer 5′-TGAAGGAGAAGG-
TGTCTGCGGGA-3′ and reverse primer 5′-AGGACGG-
TGCGGTCA GAGTG-3′. PCR thermal cycling conditions 
were a 2-min denaturation period at 94℃ and 40 cycles of 
the following：94℃ for 30sec, 62℃ for 30sec, and 72℃ 
for 30sec. This was followed by a 7-min extension at 72℃. 
The 50μl PCR mixture contained 10mM Tris.HCl(pH 8.3), 
50mM KCl, 2.5mM MgCl2, 0.1mg/ml gelatin, 200μM each 
dNTP, and 1.25 units of Taq DNA polymerase.  
HinfI restriction digestion using 2.5μl of buffer and 10 
units of HinfI restriction enzyme(Promega, CatalysAG, Wal-
lisellen, Switzerland) added to 25μl of PCR product was 
incubated at 37℃ for at least 3hr. Digestion products were 
visualized after electrophoresis on a 3.0% agarose gel with 
ethidium bromide. Wild-type homozygotes produced single 
band at 198-bp. Heterozygotes produced 198-, 175-, and 23-
bp fragments. Mutant homozygote produced 175- and 23-bp 
fragments(Fig. 1). Laboratory personnels were blind to the 
case-control status, and the blinded quality control samples 
were included.  
 
Statistical analysis 
All statistical analyses in this study were performed using 
198bp 
175bp 
CT CC TT 
Fig. 1. Methylenetetrahydrofolate reductase genotyping by
PCR and restriction analysis. Normal homozygotes lacking the
C677T mutation are identified by the presence of single 198-
bp fragment, whereas C677T homozygotes show single 175-bp
fragment. Heterozygotes for the C677T mutation are charac-
terized by the presence of both the 198-bp and the 175-bp fr-
agment. 
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SPSS for Windows, version 9.0(SPSS Inc., Chicago, Illinois, 
USA). Accordance with the Hardy-Weinberg equilibrium 
was checked for case and control subjects using chi-square 
test. Odds ratios and 95% CI intervals were adjusted for sex 
and age using a multivariated logistic regression. 
 
Results 
 
Among the 71 patients diagnosed with brain tumors, the 
MTHFR C677T mutant allele frequency was 0.4 compared 
with 0.39 among the 254 control subjects. The frequencies of 
MTHFR 677CC, 677CT, 677TT genotypes were 35.2%, 
49.3%, and 15.5% in the brain tumor cases and 35.8%, 
50.8%, and 13.4% in the controls, respectively.  
 
Prevalence of the MTHFR 677 genotypes in the gliomas 
Listed in Table 1 are the observed frequencies of the 
MTHFR C677T polymorphisms among the 19 glioma cases 
and 254 controls. We found the MTHFR 677CC allele pre-
sent among 6 glioma cases(31.6%) and 91 controls(35.8%), 
the 677CT genotype among 10 glioma cases(52.6%) and 129 
controls(50.8%), and 677TT allele among 3 glioma cases 
(15.8%) and 34 controls(13.4%). The effects of the MT-
HFR 677CT allele and 677TT relative to 677CC are not 
significant in the risk of glioma(OR=1.35；95% CI=0.46-
3.99 and OR = 1.53；95% CI = 0.30-7.73, respectively). 
 
Prevalence of the MTHFR 677 genotypes in the me-
ningiomas 
Frequencies of the MTHFR 677 polymorphism in the 32 
meningioma cases and 254 controls are listed in Table 2. For 
677CC, 677CT, and 677TT, we observed 16(50.0%), 13 
(40.6%), and 3(9.4%) meningioma cases, respectively. Di-
fferent proportions were found among their controls；that is, 
91(35.8%) were 677CC, 129(50.8%) were 677CT, and 34 
(13.4%) were 677TT. Significant differences were observed 
for 677CT or 677TT compared with 677CC(OR=0.53；
95% CI=0.24-1.17 and OR=0.42；95% CI=0.11-1.58, re-
spectively). 
 
Prevalence of the MTHFR 677 genotypes in the sch-
wannomas 
The frequencies of 677CC, 677CT and 677TT genotypes 
among the controls were 3(15.0%), 12(60.0%) and 5(25. 
0%), respectively(Table 3). The frequency of 677TT ge-
notype among the schwannoma cases(25.0%) was higher 
compared with that of the controls(13.4%)；the age- and 
sex-adjusted OR for this genotype was 4.75(95% CI=1.05-
21.50). 
 
Discussion 
 
The relationship between folate status and the risk of 
developing several diseases, including cardiovascular disease, 
neural tube defects, and tumor has been a topic of intense 
interest in the field of folate nutrition21,22,29,38). In the area of 
folate and tumorigenesis, several potential mechanisms by 
which folate status can modulate tumorigenesis have been 
linked to the disruption of the essential biochemical function 
of folate9,22). The sole biochemical function known for folate 
is that of mediating the transfer of one-carbon moieties37). In 
this role, folate is critical for the synthesis of S-adenosylme-
thionine, a compound that serves as the methyl donor for 
more than 100 biologic methylation reactions, including that 
of DNA33). DNA methylation is an important epigenetic 
determinant in gene expression, DNA stability and integrity, 
and mutagenesis3,40). Folate is also an essential factor for the 
Table 2. Number of meningiomas and controls, adjusted odds 
ratio and 95% confidence index by MTHFR 677, using 677CC 
as a reference 
Genotype Case Control Odds ratio 95% CI* 
CC(reference) 16(50.0) 091(35.8) 1 - 
CT 13(40.6) 129(50.8) 0.53 (0.24-1.17) 
TT 03(09.4) 034(13.4) 0.42 (0.11-1.58) 
Adjusted for age and sex. Percentages are in parentheses. 
*CI：confidence index 
Table 1. Number of gliomas and controls, adjusted odds ratio
and 95% confidence index by MTHFR 677, using 677CC as a
reference 
Genotype Case Control Odds ratio 95% CI* 
CC(reference) 06(31.6) 091(35.8) 1 - 
CT 10(52.6) 129(50.8) 1.35 (0.46-3.99) 
TT 03(15.8) 034(13.4) 1.53 (0.30-7.73) 
Adjusted for age and sex. Percentages are in parentheses. 
*CI：confidence index 
Table 3. Number of schwannomas and controls, adjusted odds 
ratio and 95% confidence index by MTHFR 677, using 677CC 
as a reference 
Genotype Case Control Odds ratio 95% CI* 
CC(reference) 03(15.0) 091(35.8) 1 - 
CT 12(60.0) 129(50.8) 2.88 (0.78-10.56) 
TT 05(25.0) 034(13.4) 4.75 (1.05-21.50) 
Adjusted for age and sex. Percentages are in parentheses. 
*CI：confidence index 
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de novo biosynthesis of purines and thymidylate, and hence 
plays an important role in DNA replication and repair37). 
Aberrant patterns of DNA methylation, unrepaired DNA 
damage and impaired DNA repair have all been implicated 
in carcinogenesis3,9,22,40). The possible contribution of several 
enzymes involved in folate metabolism that are essential to 
folate-mediated carcinogenesis has just begun to be recogni-
zed. Recently, common genetic polymorphisms of MTHFR 
have been observed to modulate the risk of developing 
cardiovascular disease, neural tube defects, and cancers1). 
MTHFR is a critical enzyme in folate metabolism. MTHFR 
catalyzes the biologically irreversible reduction of 5,10-
methylene THF to 5-methyl THF. A common mutation 
(677C→T, alanine→valine) has been identified in the MT-
HFR gene16,19). The frequency of the 677C→T polymorphism 
of MTHFR varies among racial and ethnic groups. The 
analysis of Caucasian and Asian populations typically shows 
rates of -12% for those who are homozygous and up to 50% 
for those of who are heterozygous7,16). Among 677TT indivi-
duals, the MTHFR enzyme is less efficient in converting 
5,10-methylene THF to 5-methyl THF, thus potentially pre-
venting depletion of 5,10-methylene THF, a cofactor for de 
novo synthesis of nucleotides necessary for DNA synthesis, 
especially dTMP(Fig. 2). As a result, cells may be less 
prone to “dTMP stress,” which has been shown to promote 
cancer-associated genetic alterations21) due to alterations in 
the pool of nucleotide precursors available for DNA syn-
thesis. Alteration in these precursor pools induced by methyl 
folate deficiency significantly increases the uracil content 
and the frequency of chromosome breaks in human leukocyte 
DNA5). 
With respect cancer risk, the 677C→T polymorphism of 
MTHFR appears to be protective against the development of 
colorectal cancer and acute lymphocytic leukemia8,26,36), 
whereas it enhances the risk of endometrial12) and gastric 
cancers35). In various cancers, the MTHFR 677C→T poly-
morphism modulates carcinogenesis in a site- and stage-
specific manner. In the present study, we report an asso-
ciation of the susceptibility to the several types of brain 
neoplasms with the polymorphism in the gene encoding the 
enzyme MTHFR. We observed that the 677C→T mutation 
in MTHFR was associated with the reduced risk of meni-
ngiomas and the increased risk of schwannomas. How can 
we explain these different results in benign brain tumors? 
First, we suspect that our study had limited statistical power 
because of the small sample size, which is reflected in the 
wide CIs. Hence, these findings need to be confirmed in 
larger populations. Second, we guess that there can be the 
different mechanisms of sporadic tumorigenesis. The genome 
of the transformed cell undergoes simultaneously a global 
genomic hypomethylation and a dense hypermethylation of 
the CpG islands associated with gene regulatory regions. 
These dramatic changes may lead to chromosomal instability, 
activation of endogenous parasitic sequences, loss of imprin-
ting, illegitimate expression, aneuploidy, and mutations, and 
may contribute to the transcriptional silencing of tumor 
suppressor genes13,17). DNA methy-
lation patterns in hereditary human 
cancers mimic sporadic tumorige-
nesis11). There are some reports of 
aberrant expression or mutation of 
the promotor elements in schwan-
noma or meningioma6,24,39). In this 
study, unfortunately, we did not 
measure the level of methylation, 
homocysteine, folate and MTHFR 
enzyme activity in the brain tumor 
tissues. In the future, studies as 
follow are warranted；the relati-
onship of DNA methylation with 
brain tumors, the development of 
brain tumors in MTHFR knock-
out mice, and the establishment of 
a cause-and-effect relationship. 
Folic acid 
Deoxyuridylate 
dUMP 
THF 
5,10-methylene THF 
5-methyl THF 
MTHFR 
Homocysteine 
betaine 
methyltransferase 
Methionine 
SAM 
SAH 
MS 
B12 
betaine 
DNA methylation 
10-formy THF 
Purine 
Thymidylate 
dTMP 
DNA synthesis 
Dihydrofolate 
Fig. 2. Simplified scheme of the metabolic role of methylenetetrahydrofolate reductase in folate 
metabolism involving DNA methylation and DNA synthesis. THF：tetrahydrofolate, MTHFR：
methylenetetrahydrofolate reductase, MS：methionine synthetase, B12：vitamin B12, SAM：S-
adenosylmethionine, SAH：S-adenosyl homocysteine. 
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Conclusion 
 
Our data suggest that the MTHFR enzyme activity plays 
an important role in schwannoma and meningioma. Brain 
tumor is a relatively rare disease, making it difficult to perfo-
rm a large epidemiological study, but studies in multicenters 
should be undertaken to confirm the findings presented here. 
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